Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 3;11(1):1-11.
doi: 10.1080/21556660.2022.2073101. eCollection 2022.

A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen

Crystal Watson  1 , Hemanth Gadikota  2 , Arie Barlev  1 , Rachel Beckerman  2
Affiliations

A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen

Crystal Watson et al. J Drug Assess. .

Abstract

A common chemotherapy regimen in post-transplant lymphoproliferative disease (PTLD) following solid organ transplants (SOT) is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). This study reviews the quantitative evidence for long-term consequences associated with components of CHOP identified from the Children's Oncology Group Long-Term Follow-Up Guidelines. Cited references were screened using prespecified criteria (English, systematic review, randomized controlled trial n > 100, observation study n > 100, case series n > 20). Relevant data were extracted and synthesized. Of 61 studies, 66% were retrospective cohort studies, 28% were in the US, and 95% enrolled pediatric patients. No study focused specifically on the CHOP regimen. Long-term consequences for CHOP components observed in >3 studies included cardiac toxicity (n = 14), hormone deficiencies/infertility (n = 14), secondary leukemia (n = 7), osteonecrosis (n = 6), and bladder cancer (n = 4). These effects are significant, impact a high percentage of patients, and occur as early as one year after treatment. Although none of the studies focused specifically on the CHOP regimen, 30%, 23%, and 15% evaluated alkylating agents (e.g. cyclophosphamide), anthracyclines (e.g. doxorubicin), and corticosteroids (e.g. prednisone), respectively. All three product classes had a dose-dependent risk of long-term consequences with up to 13.2-fold, 27-fold, 16-fold, 14.5-fold, and 6.2-fold increase in risk of heart failure, early menopause, secondary leukemia, bladder cancer, and osteonecrosis, respectively. Lymphoma patients had significantly elevated risks of cardiac toxicity (up to 12.2-fold), ovarian failure (up to 3.8-fold), and osteonecrosis (up to 6.7-fold). No studies were found in PTLD or SOT. Safe and effective PTLD treatments that potentially avoid these long-term consequences are urgently needed.

Keywords: CHOP; adverse events; long-term outcomes; lymphoproliferative disease; stem cell transplant.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA Flowchart.
Figure 2.
Figure 2.
Characteristics of included studies.
See this image and copyright information in PMC

References

    1. Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant. 2013;(13 Suppl 4):1–120. - PubMed
    1. Parker A, Bowles K, Bradley JA, Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society, et al.. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS guidelines. Br J Haematol. 2010;149(5):693–705. - PubMed
    1. Styczynski J, van der Velden W, Fox CP, Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN), et al.. Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth European Conference on infections in leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803–811. - PMC - PubMed
    1. Blaes AH, Peterson BA, Bartlett N, et al. . Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer. 2005;104(8):1661–1667. - PubMed
    1. Choquet S, Leblond V, Herbrecht R, et al. . Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107(8):3053–3057. - PubMed